PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples.
CD8 positive lymphocytes
PD-L1
human cancers
immunohistochemistry
tissue microarray
Journal
Cancer biomarkers : section A of Disease markers
ISSN: 1875-8592
Titre abrégé: Cancer Biomark
Pays: Netherlands
ID NLM: 101256509
Informations de publication
Date de publication:
2023
2023
Historique:
pubmed:
24
1
2023
medline:
15
2
2023
entrez:
23
1
2023
Statut:
ppublish
Résumé
Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes. At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin's lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma (p< 0.0001 each). PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.
Sections du résumé
BACKGROUND
BACKGROUND
Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking.
MATERIALS AND METHODS
METHODS
We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes.
RESULTS
RESULTS
At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin's lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma (p< 0.0001 each).
CONCLUSIONS
CONCLUSIONS
PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.
Identifiants
pubmed: 36683495
pii: CBM220030
doi: 10.3233/CBM-220030
pmc: PMC9986704
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-191Références
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Oral Oncol. 2020 Feb;101:104492
pubmed: 31837576
Int J Clin Oncol. 2015 Apr;20(2):273-81
pubmed: 24804867
J Clin Oncol. 2017 Dec 1;35(34):3867-3876
pubmed: 29053400
Ann Oncol. 2015 Jul;26(7):1488-93
pubmed: 25897014
Mod Pathol. 2017 Mar;30(3):427-439
pubmed: 27934877
Eur Rev Med Pharmacol Sci. 2015 Aug;19(16):3063-71
pubmed: 26367730
Pathology. 2017 Aug;49(5):506-513
pubmed: 28688724
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31959726
Oncotarget. 2017 Apr 18;8(16):26789-26801
pubmed: 28460462
Cancer Med. 2017 Jul;6(7):1673-1685
pubmed: 28556593
Methods Mol Biol. 2016;1381:53-65
pubmed: 26667454
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Curr Drug Targets. 2020;21(13):1286-1292
pubmed: 31971109
Front Oncol. 2020 Aug 12;10:1161
pubmed: 32903606
Onco Targets Ther. 2020 Jul 03;13:6475-6483
pubmed: 32753888
Esophagus. 2021 Jan;18(1):90-99
pubmed: 33170461
Pathol Oncol Res. 2020 Oct;26(4):2733-2745
pubmed: 32681436
Ann Diagn Pathol. 2019 Aug;41:24-37
pubmed: 31132649
Cancer Manag Res. 2020 Jun 03;12:4161-4168
pubmed: 32581587
Mod Pathol. 2019 Nov;32(11):1646-1656
pubmed: 31231126
Histopathology. 2017 Sep;71(3):357-365
pubmed: 28383817
Oral Oncol. 2019 May;92:33-39
pubmed: 31010620
Oncotarget. 2018 Jan 12;9(9):8584-8596
pubmed: 29492219
Int J Oncol. 2020 Jul;57(1):237-248
pubmed: 32468013
Ann Surg. 2019 Mar;269(3):471-478
pubmed: 29206673
Front Med (Lausanne). 2020 Jun 05;7:198
pubmed: 32582722
South Asian J Cancer. 2021 Apr;10(2):72-75
pubmed: 34568218
Int J Clin Oncol. 2020 May;25(5):818-830
pubmed: 31549270
Balkan Med J. 2018 Dec 28;36(3):184-189
pubmed: 30592196
Sci Rep. 2019 May 1;9(1):6769
pubmed: 31043675
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
Gut. 2017 Aug;66(8):1463-1473
pubmed: 27196573
J Transl Med. 2018 Nov 6;16(1):303
pubmed: 30400799
Am J Pathol. 2001 Apr;158(4):1245-51
pubmed: 11290542
Eur J Cancer. 2015 Nov;51(17):2698-707
pubmed: 26329973
BMC Cancer. 2019 Feb 12;19(1):142
pubmed: 30755167
Mod Pathol. 2021 Feb;34(2):252-263
pubmed: 32884129
Gut. 2017 May;66(5):794-801
pubmed: 26801886
Hum Pathol. 2016 Jun;52:9-18
pubmed: 26980049
Am J Dermatopathol. 2021 Aug 1;43(8):556-559
pubmed: 33156018
Br J Cancer. 2019 May;120(11):1033-1036
pubmed: 31061454
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Nature. 2015 Jan 1;517(7532):109-10
pubmed: 25557714
Medicina (Kaunas). 2019 Oct 31;55(11):
pubmed: 31683723
Hum Pathol. 2016 Jan;47(1):52-63
pubmed: 26527522
Cancer Cell. 2019 Aug 12;36(2):168-178.e4
pubmed: 31327656
Eur J Cancer. 2016 Mar;55:7-14
pubmed: 26771872
Mod Pathol. 2020 Jan;33(1):4-17
pubmed: 31383961
JAMA Oncol. 2020 Oct 1;6(10):1563-1570
pubmed: 32852531
Am J Pathol. 2001 Dec;159(6):2249-56
pubmed: 11733374
Cancer Res. 2019 Apr 1;79(7):1493-1506
pubmed: 30679180
Oncotarget. 2019 Feb 22;10(16):1572-1588
pubmed: 30899426
Am J Surg Pathol. 2016 Aug;40(8):1133-42
pubmed: 27158757
PLoS One. 2015 Aug 27;10(8):e0136023
pubmed: 26313362
Esophagus. 2021 Oct;18(4):835-843
pubmed: 33993388
Oncologist. 2017 Oct;22(10):1149-1151
pubmed: 28778959
Int J Mol Sci. 2020 Dec 06;21(23):
pubmed: 33291277
Aging (Albany NY). 2021 Jun 3;13(11):14590-14603
pubmed: 34083496
Am J Surg Pathol. 2002 Mar;26(3):312-9
pubmed: 11859202
Oncotarget. 2017 Dec 04;9(12):10284-10293
pubmed: 29535806
J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9
pubmed: 8683636
J Natl Cancer Inst. 1997 Apr 16;89(8):585-6
pubmed: 9106651
J Cancer Res Clin Oncol. 2019 Jul;145(7):1785-1794
pubmed: 31129768
Clin Cancer Res. 2017 Jul 15;23(14):3585-3591
pubmed: 28073845
Int J Gynecol Cancer. 2020 Jan;30(1):139-143
pubmed: 31645423
Mod Pathol. 2004 Nov;17(11):1414-20
pubmed: 15205686
Curr Oncol Rep. 2018 Aug 18;20(9):75
pubmed: 30120592
Lab Invest. 2000 Dec;80(12):1943-9
pubmed: 11140706
Mod Pathol. 2020 Nov;33(11):2221-2232
pubmed: 32612248
Asia Pac J Clin Oncol. 2018 Feb;14(1):69-73
pubmed: 29105302
J Cancer Res Clin Oncol. 2020 Oct;146(10):2607-2620
pubmed: 32388585